Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme/Isis’ Mipomersen Development Outlook Pricier And Riskier After FDA Weighs In

This article was originally published in The Pink Sheet Daily

Executive Summary

Cardiotoxicity and outcomes requirements push back NDA timeline for the novel LDL-lowering drug.

You may also be interested in...



Top Ten Unpartnered Drugs: It's Tough To Make The Grade In CVD/Metabolics

Early-stage talent parade will be held at Windhover's Therapeutic Area Partnerships conference next week.

Top Ten Unpartnered Drugs: It's Tough To Make The Grade In CVD/Metabolics

Early-stage talent parade will be held at Windhover's Therapeutic Area Partnerships conference next week.

GSK Goes To The Heart Of The Problem With Outcomes Study For Darapladib

GlaxoSmithKline is applying a lesson the pharmaceutical industry learned from recent events in cardiovascular drug development: do an outcomes study, and start it early

Related Content

Topics

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel